Preclinical targeting of the tumor microenvironment: Possibilities and consequences

Arjaans, M., 2015, [Groningen]: University of Groningen. 150 p.

Research output: ThesisThesis fully internal (DIV)

Copy link to clipboard


  • Title and contents

    Final publisher's version, 186 KB, PDF document

  • Chapter 1

    Final publisher's version, 222 KB, PDF document

  • Chapter 2

    Final publisher's version, 5.52 MB, PDF document

  • Chapter 3

    Final publisher's version, 4.73 MB, PDF document

  • Chapter 4

    Final publisher's version, 2.4 MB, PDF document

  • Chapter 5A

    Final publisher's version, 3.41 MB, PDF document

  • Chapter 5B

    Final publisher's version, 226 KB, PDF document

  • Chapter 6

    Final publisher's version, 392 KB, PDF document

  • Chapter 7

    Final publisher's version, 286 KB, PDF document

  • Chapter 8

    Final publisher's version, 254 KB, PDF document

  • Acknowledgements

    Final publisher's version, 227 KB, PDF document

  • Complete dissertation

    Final publisher's version, 15.7 MB, PDF document

  • Propositions

    Final publisher's version, 123 KB, PDF document

  • Marlous Arjaans
Metastatic disease is currently the main cause of all cancer induced deaths. Therefore, there is an ongoing search for new treatment strategies that may increase treatment effects. However, the importance of the tumor microenvironment as a contributor to tumor growth and metastatic disease has become more evident. This provides the rational for targeting not only the cancer cells, but also the tumor microenvironment, in order to aim to improve cancer treatment. To enable accurate targeting, it is essential to identify key targets present in the tumor microenvironment. Two potential targets present in the tumor microenvironment are transforming growth factor (TGF)-β and vascular endothelial growth factor (VEGF).

The tumor and its microenvironment are reproduced in preclinical models consisting of both stromal and cancer cells. These in vitro and in vivo models show that stromal cells are needed to exert the TGF-β mediated anti-breast cancer effect of the bisphosphonate zoledronic acid. In addition, the preclinical development of a TGF-β tracer is described. With this technique, a radiolabeled antibody can be depicted with the help of positron emission tomography (PET). With the use of the TGF-β tracer it was possible to portray the presence of TGF-β in tumors.
For VEGF, the effect of anti-VEGF therapy on tumor uptake of drugs was evaluated with the help of PET imaging. Anti-VEGF therapy reduced tumor uptake of other drugs in two preclinical models.

In conclusion, this thesis describes the possibilities and consequences of targeting factors present in the tumor microenvironment.
Original languageEnglish
QualificationDoctor of Philosophy
Awarding Institution
Award date15-Apr-2015
Place of Publication[Groningen]
Publication statusPublished - 2015

Download statistics

No data available

ID: 17532979